Company Overview

Development Stage

About the Company

[Summary] Discovery and development of innovative drugs, as well as clinical res

Shanghai Junshi Biosciences Co., Ltd. is a joint-stock company established in China on December 27, 2012. The company's main business includes: research and development of new drugs and related technology transfer and services, as well as production and sales of new drugs. The technical services provided by the company refer to customized services offered to clients using its technology platforms, including design and modification of molecular sequences, construction of high-expression cell lines, process research at pilot and scale-up levels, preclinical research, and preparation of clinical study samples. The company has accumulated a large number of core technologies, some of which are general-purpose and can be converted into services to generate revenue for clients. As of the signing date of this public transfer prospectus, the company has six drugs officially approved for research and development. The two most advanced in terms of progress are recombinant humanized anti-PD-1 monoclonal antibody injection (JS001) and recombinant humanized anti-PCSK9 monoclonal antibody injection (JS002). These two...
View all▼

Expand
Information is aggregated from the web and may not be exact. For reference only.
Information incorrect? Claim this company to edit

Junshi Biosciences Financing History (1 rounds)

Manage
IPO上市
Capital Market Favor
Latest Financing Round
  • Date: ?
  • Market:
  • Deal: 上交所

Junshi Biosciences How Fast Is Hiring Growing? (341 open positions)

Manage
Note: How fast is hiring at Shanghai Junshi Biosciences Co., Ltd. growing? Junshi Biosciences2026: 638 openings (up 108%), 2025: 307 openings (up 90%), 2024: 162 openings (down 38%), 2023: 262 openings (up 19%), 2022: 220 openings (down 45%), 2021: 397 openings. A rising curve may indicate expansion; a falling curve may indicate slower growth or good retention. Based on publicly available data, for reference only.

Junshi Biosciences Master's Degree Job Demand Analysis

(More)
?
Growth Rate
2026 vs 2025
  • 2025: Up 175%
  • 2024: Down 20%
  • 2023: Down 21%
  • 2022: Up 36%
Junshi Biosciences Master's Hiring by Year:
* Hiring was generally low during 2020-2022 due to the pandemic
How fast is master's hiring at Shanghai Junshi Biosciences Co., Ltd. growing? Junshi BiosciencesMaster's recruitment over the years: 2025: 33 openings (up 175%), 2024: 12 openings (down 20%), 2023: 15 openings (down 21%), 2022: 19 openings (up 36%), 2021: 14 openings.

Junshi Biosciences R&D Strength (Technical Talent Demand)

(More)
How is the demand for technical talent at Shanghai Junshi Biosciences Co., Ltd.? Based on an analysis of Junshi Biosciences's job postings over the past year, "计算机/网络/技术类" demand: 30.5%, "生物/制药/化工/环保类": 13.3%, "医疗卫生/美容保健类": 11.5%, "其他(研发和技术类)": 4.9%, "科研类": 3.5%, "机械/仪器仪表类": 1.2%. For reference only.

Junshi Biosciences — What Are the Salaries Like? (568 records)

Manage
salary range: 2K - 50K, 49.3% of roles pay ¥8-15K
Note: salary statistics are based on 568 salary records from the past year and depend on the job sample. For reference only.
How is the salary at Shanghai Junshi Biosciences Co., Ltd.?Junshi Biosciences49.3% of positions earn 8-15K, Fresh graduate salary: ¥2.7K。销售类 average salary ¥13.8K。 Note: Based on analysis of job postings, does not represent current on-the-job positions; system stability may affect objectivity. For reference only.Data inaccurate? Let us know

Salaries for hot jobs of Junshi Biosciences

(More)
Are salaries high at Shanghai Junshi Biosciences Co., Ltd.? We provide: 信息,实习生,医药代表,产品经理,医学顾问,研究员,销售,质量,地区经理,市场,bp,合规,运营,ra,事务专员,临床,分析,财务,细胞培养,医学经理. Click to view detailed salary analysis by job.

Junshi Biosciences honors, qualifications & industry associations

Junshi Biosciences Related Industry Tags

Job Category

  • 销售类
    50.6% of total 50.6%
  • 计算机/网络/技术类
    31.5% of total 31.5%
  • 医疗卫生/美容保健类
    18.7% of total 18.7%
  • 生物/制药/化工/环保类
    12.6% of total 12.6%

Education

  • 本科
    73.2% of total 73.2%
  • 硕士
    12.3% of total 12.3%
  • 大专
    10% of total 10%
  • 不限
    4.4% of total 4.4%

Experience

  • 不限
    35.2% of total 35.2%
  • 1-3年
    27.8% of total 27.8%
  • 5-10年
    20.9% of total 20.9%
  • 3-5年
    13% of total 13%
View Detailed Analysis

What does Shanghai Junshi Biosciences Co., Ltd. require? Who is Junshi Biosciences hiring? Junshi Biosciences recruitment: 销售类占比最多占50.6%,其次是计算机/网络/技术类占31.5%. What education can get in at Junshi Biosciences? 本科占比最多占73.2%,其次是硕士占12.3%. High education required at Junshi Biosciences? 硕士占12.3%,博士占0.1%. Work experience required at Junshi Biosciences? 不限占比最多占35.2%,其次是1-3年占27.8%. Where are the job locations at Junshi Biosciences? 上海占比最多占34.5%,其次是苏州占9.3%. Based on job postings from the past year, for reference only.

Business Registration

Provided by

Operating Status: 开业
Registered Capital: 98,568.9871万(元)
Legal Representative: 熊俊
Date Established:
Credit Code: 91310000059383413A
Registered Address: 中国(上海)自由贸易试验区蔡伦路987号4层

Partners & Suppliers

澎立生物为君实生物提供临床前安全性评价服务 Source
供应商 制药企业
委托益诺思进行非临床安全性评价 Source
供应商 非临床CRO服务-客户
为君实生物特瑞普利单抗提供患者福利项目管理和商业保险支付方案,减轻患者用药负担。 Source
供应商 患者援助及创新支付
君实生物将特瑞普利单抗在欧盟、欧洲经济区、英国、瑞士等地区的权利授权给利奥制药,君实获得首付款及里程碑付款。 Source
合作客户 对外授权合作
君实生物将特瑞普利单抗在泰国、印度尼西亚、菲律宾等东南亚九国的开发和商业化权利授权给康联达,君实获得首付款和销售分成。 Source
合作客户 对外授权合作

People who follow Junshi Biosciences also follow

Junshi Biosciences Competitors (Similar Companies)

“Research, development, and production of anti-tumor and surgical medic”
“Continuously innovating to bring patients medicines that significantly”
“To develop high-quality biologics that are accessible and affordable f”
生物科技/生物工程 蛋白质工程 药物研发 生物制药
“Focused on three major fields: healthcare, life science, and electroni”
“In the rapidly growing biopharmaceutical field, accelerate and transfo”
“A renowned enterprise in China's liver disease and anti-tumor fields”
“Promoting human health”
“Dedicated to the research and development of molecularly targeted drug”
“Global integrated biopharmaceutical enterprise”
“An innovative biopharmaceutical enterprise focusing on antibody drugs”
制药/药业 抗肿瘤药 肿瘤检测 神经系统疾病药物
“Provides consulting and services to over one hundred pharmaceutical ma”
“A provider of overall products, solutions, and services in the medical”
“Technological innovation and commercial application of pharmaceutical ”

Report

*Reason:

Radical political or ideological topics
Advertising or spam
Pornographic or vulgar content
Obscene language or personal attacks
Other

Congratulations, submitted successfully!

Your edit is under review. You will be notified by email within 1 business day.

Submission failed.

Followed successfully. We'll notify you of any company updates.

Help others learn about this company, add my impression of this company»

Log in with the following accounts to save your follows

Followed successfully, we'll notify you of any company updates